title: [A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer].
abstract: A 7 0-year-old female underwent distal gastrectomy for gastric cancer in November 2001. She did not wish to receive postoperative adjuvant chemotherapy. In May 2002, her serum carcinoembryonic antigen(CEA)level rose. CT demonstrated liver(S5/6)and lung(S9)metastases in August 2002. We started to treat her with S-1(100mg/day day 1-14 orally), and restaging CT showed complete regression of liver and lung metastases in August 2003. In spite her complete response(CR), we continued S-1 treatment for the successive two years. No adverse reaction to chemotherapy occurred. Although CR was maintained for about 4 years, she was found to have a 9-mm solitary lesion in the upper pole of the spleen in June 2007. After 6 months, this tumor increased to 15mm in size, and we considered it as a solitary metastasis to the spleen from gastric cancer. S-1 chemotherapy was restarted, but tumor size gradually increased. Tumor size finally reached 25mm in December 2008. She underwent splenectomy in January 2009. From then until now, she has not received any chemotherapy, and has been followed well without any recurrence.
authors.affiliation: Department of Surgery, Asahi General Hospital.
authors.forename: Masaharu
authors.initials: M
authors.lastname: Ogura
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Tanaka
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Furuya
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Nomura
authors.forename: Motoki
authors.initials: M
authors.lastname: Nagai
authors.forename: Michiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Toshio
authors.initials: T
authors.lastname: Takayama
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Hirao
authors.forename: Hogara
authors.initials: H
authors.lastname: Nakamura
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Suzuki
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005763:Gastroenterostomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009362:Neoplasm Metastasis; D010094:Oxonic Acid / Q000627:therapeutic use*; D012074:Remission Induction; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid